BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 25403716)

  • 1. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
    Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
    J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
    Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
    Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.
    Mandapathil M; Hilldorfer B; Szczepanski MJ; Czystowska M; Szajnik M; Ren J; Lang S; Jackson EK; Gorelik E; Whiteside TL
    J Biol Chem; 2010 Mar; 285(10):7176-86. PubMed ID: 19858205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.
    Clayton A; Al-Taei S; Webber J; Mason MD; Tabi Z
    J Immunol; 2011 Jul; 187(2):676-83. PubMed ID: 21677139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
    Sun X; Wu Y; Gao W; Enjyoji K; Csizmadia E; Müller CE; Murakami T; Robson SC
    Gastroenterology; 2010 Sep; 139(3):1030-40. PubMed ID: 20546740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abnormal function of CD39
    Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
    Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
    Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
    Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
    Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
    J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
    Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
    J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine Generated by Regulatory T Cells Induces CD8
    Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
    Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENTPD1/CD39 is a promising therapeutic target in oncology.
    Bastid J; Cottalorda-Regairaz A; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A
    Oncogene; 2013 Apr; 32(14):1743-51. PubMed ID: 22751118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD73 and adenosine generation in the creation of regulatory microenvironments.
    Regateiro FS; Cobbold SP; Waldmann H
    Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
    Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
    FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
    Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
    Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.